China's biopharmaceutical industry is rapidly rising to become a new driving force for steady growth

         In the modern biopharmaceutical production workshop of Qilu Pharmaceutical Group Co., Ltd. located in Jinan, Shandong, China's first bevacizumab biosimilar Anceda is in full production. This drug, mainly used to treat advanced, metastatic, or recurrent non-small cell lung cancer and metastatic colorectal cancer, broke the long-standing monopoly of foreign pharmaceutical giants on similar drugs in China after its launch at the end of last year, greatly enhancing the accessibility and affordability of clinical medication.

　　As one of the leading enterprises in China's pharmaceutical industry, in 2019 Qilu Pharmaceutical achieved sales revenue of 230 billion yuan, with exports of 6.15 hundred million US dollars; 2020 years ago 11 months, its product exports increased year-on-year by 14% Currently, Qilu Pharmaceutical's products have been exported to more than 70 countries and regions worldwide.

　　The biopharmaceutical industry is one of the most innovative and influential strategic emerging industries of the 21 century. Although China started late in this field, it has developed rapidly. Especially in the context of the global COVID-19 pandemic, China's complete industrial chain and strong supply capacity in the biopharmaceutical industry have not only made important contributions to the global fight against the pandemic but have also rapidly risen to become a new driving force for steady growth. " new driving force ”。

　　At the beginning of the pandemic, masks, as essential protective supplies, were once hard to find. ” Jinan city used one month to open up the entire mask production industry chain, increasing daily output from 6 ten thousand pieces by more than 400 times, providing strong material support for winning the battle against the pandemic.

　　Strictly controlling the testing checkpoint ” is one of the effective ways to reduce the risk of pandemic spread. " magic weapons ” . 2020 At the beginning of the year 2 in January, Jinan Yinfeng Medical Testing Institute (Yinfeng Gene Technology Co., Ltd.) under Yinfeng Bioengineering Group Co., Ltd. quickly became the first third-party institution for COVID-19 nucleic acid testing in Jinan. Its independently developed COVID-19 test kits have passed the European Union CE certification; the independently developed first bus-type 5G mobile nucleic acid testing laboratory in Shandong Province can achieve an average daily testing capacity of 20,000 samples.

　　Under the impact of the pandemic, many enterprises worked overtime to switch production and increase output of masks, protective clothing, ventilators, and other anti-epidemic supplies, continuously delivering them to frontlines at home and abroad. As a national high-tech enterprise, Shandong Boke Biological Industry Co., Ltd. urgently produced and shipped more than 5,000 units of biosafety equipment, air disinfectors, sterilizers, and other products within just a few months.

　　Since the outbreak of the pandemic, China has actively provided anti-epidemic supplies globally, with masks alone exceeding 2000 hundreds of millions, averaging 30 pieces per person worldwide. According to data released by the General Administration of Customs, 2020 in the first three quarters of the year, China's export of anti-epidemic supplies maintained rapid growth. Among them, textile exports including masks reached 8287.8 billion yuan, an increase of 37.5% Additionally, exports of medicinal materials and drugs, medical instruments and devices increased by 21.8% 、 and 48.2% respectively. 。

　　The export of high-end formulation products to Europe and the United States reflects the comprehensive strength of China's biopharmaceutical companies. Li Yan, president of Qilu Pharmaceutical Group Co., Ltd., introduced that currently Qilu Pharmaceutical 15 exports personal drug formulations to the United States, with injectable cefpirome, ondansetron hydrochloride injection, and solifenacin tablets holding the number one market share in the US; it is the first domestic company to export commercially packaged injections to Japan; and has achieved 9 product exports to the European market.

　　Hyaluronic acid (commonly known as " hyaluronan ” ) is widely used in orthopedics, ophthalmology, general surgery, plastic surgery, and other medical and medical device fields, as well as cosmetics and health food sectors. Zhao Yan, chairman of Bloomage BioTechnology Corporation Limited, said that relying on independent innovation, Bloomage BioTechnology was the first in China to achieve industrialization breakthrough of hyaluronic acid microbial fermentation technology, changing the backward situation where China mainly produced hyaluronic acid by animal tissue extraction and heavily relied on imports. It has reached the forefront of the world in the field of hyaluronic acid, with sales covering 40 more than countries and regions.

　　 " Innovative drugs are an important indicator of a company's innovation capability and strength, and a key driver for Chinese pharmaceutical companies to win international competition and achieve the transition from ' following to running alongside ' and in the future to leading ' . to An important grasp. ” Said Zhu Yidong, executive vice president of Qilu Innovative Drug Research Institute.

　　After 7 years, Qilu Pharmaceutical successfully developed the targeted drug gefitinib tablets (Iressa) for non-small cell lung cancer. In the more than 3 years since its launch, it has driven the price of similar imported drugs down from more than 5000 yuan per box to 500 yuan; after nearly 10 years, the bevacizumab biosimilar was successfully developed, and after its launch, the drug price also dropped significantly.

　　Represented by Qilu Pharmaceutical, Huaxi Bio, and others, Shandong has now risen a group of leading enterprises in the biopharmaceutical field. Currently, Shandong has national-level pharmaceutical innovation platforms 21 units, drug safety evaluation research centers 5 institutions, drug clinical trial organizations 61 units, with the pharmaceutical industry scale accounting for one-seventh of the national total.

　　At the same time, multiple regions in China have also formed biopharmaceutical industry clusters. 2019 In the year, Beijing's pharmaceutical and health industry overall scale exceeded 2000 billion yuan, maintaining double-digit growth for four consecutive years; currently, Suzhou, Jiangsu has gathered nearly 3000 biopharmaceutical enterprises, with nearly 5 ten thousand employees, 2020 In the first three quarters of the year, the biopharmaceutical industry achieved revenue of about 1700 billion yuan, a year-on-year increase of about 24% , and the full-year revenue is expected to exceed 2000 billion yuan.

　　 " Accelerate the speed of innovative drug research and development to continuously inject new momentum into promoting the high-quality development of China's biopharmaceutical industry. ” Said Bao Haizhong, Vice President of Qilu Pharmaceutical Group. Qilu Pharmaceutical closely follows the international trend of innovative drug development, currently having more than 50 innovative drug projects under research, with 10 projects approved to enter clinical trials, 2020 In the year, there were 11 projects applying for IND (Investigational New Drug clinical trials) in China and the United States.

　　2020 At the beginning of the year 11 The "Year 2020 China Life Sciences and Biotechnology Development Report" released in the month pointed out that since 2010 year, the number of patent applications in China has remained second in the world, 2019 year patent grants ranked first globally. Biotechnology and new drug research and development remain the two most capital-focused fields. China is second only to the United States and is the world's second largest region for intensive investment and financing.

　　In the view of Tan Yong, Vice President of the China Pharmaceutical Enterprise Management Association, China's contribution to global pharmaceutical innovation has rapidly increased in recent years. A group of biopharmaceutical companies continue to strengthen basic research and actively expand international markets, accelerating China's pace to join the global first tier of pharmaceutical innovation.